Abstract Given the failures of past HIV-1 vaccine clinical trials, potential HIV-1 vaccine candidates should be rigorously screened in preclinical models including simian immunodeficiency virus (SIV) primate models and small animal models. In this study, we tested the immunogenicity of a recombinant fowlpox virus (rFPV) expressing the SIV gag and SIV envT (rFPV sg-se ) proteins in BALB/c mice, to establish a foundation for further development. rFPV sg-se was constructed through homologous recombination techniques and purified through plaque screening assays using enhanced green fluorescent protein as the reporter gene. The integration, transcription, and translation of the SIV genes were measured by PCR (genomic DNA), RT-PCR (RNA), Western-blot, respectively. The levels of SIVspecific antibodies were assessed by ELISA following a single immunization (n = 18/group) or a prime-boost strategy (n = 24/group) with rFPV sg-se and compared to FPV and PBS controls. Residual virus was measured in distant organs following immunization using PCR. SIVspecific IgG titers against gag and gp120 were detected following single vaccination and the prime-boost. As expected the titers were higher following the prime-boost approach. The levels of Gag-and gp120-specific antibodies were significantly higher than controls (p \ 0.01) 14 days after the booster immunization. Residual rFPV Sg-Se was detected in the muscle at the site of injection, but not in distant organs, from day 1-7 post immunization. In summary, rFPV sg-se induced high levels of SIV-specific antibodies suggesting it may be a viable candidate for further development.
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Introduction
Despite the fact that human immunodeficiency virus-1 (HIV-1) was discovered more than 30 years ago, there is an urgent need for a safe and effective global HIV-1 vaccine. While HIV-1 vaccine clinical efficacy trials have not been stopped, only four vaccine concepts have been evaluated for protective efficacy in humans [1, 2] . However, the tested vaccines ultimately failed to provide sufficient protection against HIV infection in clinical trials [3] . One of the lessons learned from these failures was that HIV-1 vaccines should be evaluated first in stringent preclinical studies [2] . Fowlpox virus (FPV) has been used as a live vector vaccines against infectious diseases and cancer in poultry, humans, and other mammals, and has been shown to be safe [4] [5] [6] [7] , which was directly correlated with variable regions 1 and 2 (V1V2) of the HIV-1 envelope (Env) IgG antibodies and Env-specific IgA antibodies that were elicited [8] . This result suggested that Env proteins could be used to elicit broadly neutralizing antibodies against HIV-1 and/or simian immunodeficiency virus (SIV) [9] [10] [11] . However, broadly neutralizing antibodies are difficult to induce because of their unique characteristics [12] . Therefore, an alternative approach is to elicit antibodies that are similar to neutralizing antibodies and able to neutralize many HIV-1 strains [13] [14] [15] [16] . In addition to Env, HIV-1 gag and SIV gag can also elicit high frequencies of gag-specific CD8
? T cells and a longlasting humoral response [17] [18] [19] . Therefore, the gag and env proteins would likely be the preferred antigen for use in a recombinant FPV (rFPV) vaccine candidate.
As previously noted, HIV-1 vaccine candidates should be extensively studied in stringent preclinical models prior to human efficacy studies. SIV infection in rhesus macaque monkeys is one such system which has been used for evaluating HIV-1 vaccine. Thus, the first step in developing an rFPV HIV-1 vaccine, is developing an rFPV vaccine expressing SIV antigens that can be experimentally tested in the preclinical models to estimate the immunogenicity and protective efficacy of the SIV/HIV vaccine candidates. However, the macaque model is limited in that the experiments are expensive, use outbred animals, and use relatively small numbers of animals. Therefore, the immunogenicity of candidate vaccines are often tested in small animal models prior to primate studies.
Therefore, in this study we constructed an rFPV vaccine expressing the SIV gag and SIV envT genes to evaluate the immunogenicity of the rFPV-gag/env vaccine in BALB/c mice to provide a foundation for evaluating the vaccine construct in the macaque model.
Materials and Methods
Plasmid, Virus, Cells and Animals pVR-SIV gag and pVR-SIV envT were kindly provided by Xia Feng at the Chinese Center for Disease Control and Prevention. The gag and envT genes belong to the SIV/-mac239 (Genebank accession #M33262), envT was constructed by truncating env.
The rFPV vaccine was constructed from the Chinese FPV vaccine strain FPV282E4 and an FPV shuttle vector. The plasmid pVAX-Cre and FPV shuttle vectors were constructed previously. FPV282E4 was purchased from the Animal Pharmaceutical Factory of Nanjing (Nanjing, China). Baby hamster kidney (BHK) cells were cultured in DMEM with 10% fetal bovine serum and 1% penicillin (10,000 U/mL) / streptomycin (10,000 lg/mL) solution. Eight-day-old specific-pathogen free chickens were used to prepare the chick embryo fibroblast (CEF) cells that were purchased from Meiliyaweitong Experimental Animal Technology Co. Ltd (Beijing, China).
Six-week-old, female BALB/c mice (Experimental Animal Center, Academy of Military Medical Sciences of PLA, Beijing, China) were housed in an animal facility.
Construction of Recombinant Plasmids
The FPV shuttle vector pT3eGFP150 (4816 bp) containing the left (TKL) and right (TKR) halves of the TK gene, a double-gene expression cassette, and EGFP reporter gene was constructed in our laboratory [20] . The 1.5 kb SIV gag and 2.1 kb SIV envT genes were amplified and cloned into the multiple cloning site (MCS) 1 and MCS 2 respectively, to produce pT3eGFP150-SIV gag-SIV envT (pT3eGFP-Sg-Se).
Isolation of rFPV Sg-Se from CEF Cells
CEF cells were infected with FPV282E4 at a multiplicity of infection (MOI) of 1 for 2 h. The cells were then transfected with 1 lg of the plasmid pT3eGFP150-Sg-Se using Lipofectamine 2000 (Invitrogen, US). The infected cells expressing EGFP were picked out under a fluorescence microscope and used for additional rounds of infection. After 12 rounds of plaque screening, the purified virus was termed rFPV Sg-Se . rFPV Sg-Se was then characterized by PCR, RT-PCR, and Western-blot.
Characterization of rFPV Sg-Se
The genomic DNA (gDNA) and total RNA from cells infected with rFPV Sg-Se were extracted to use as templates for amplifying the SIV gag, SIV envT, FPV-P4b, and TK genes by PCR and RT-PCR. The PCR reaction conditions were 95°C 5 min, 30 cycles of 95°C 30 s, 60°C 30 s and 72°C 2 min 10 s, and a final extension at 72°C for 10 min. The primers utilized are shown in Table 1 . The SIV gag and SIV envT genes were inserted into the FPV genome such that the TK gene was broken and blocked, therefore the TK gene was used as a selection marker to purify rFPV Sg-Se . The P4b gene encoding the virion nucleoprotein (75 kDa), which is widely found in FPV, was used to identify FPV [21] .
Considering the characteristics of FPV, we need to test the target proteins whether could be expressed effectively in rFPV Sg-Se -infected BHK cells. Therefore, BHK cells were infected with rFPV Sg-Se at an MOI of 5 for 72 h, and total protein was extracted from rFPV Sg-Se -infected cells to probe for expression of the SIV gag and SIV envT proteins by Western-blot. A rabbit anti-p27 (SIV/mac 239) antibody, rabbit anti-gp120/160 (SIV/mac239) antibody, and mouse anti-b-actin antibody were used as the primary antibodies to identify the SIV gag, SIV envT and b-actin proteins, respectively. HRP-conjugated goat anti-rabbit lgG and goat anti-mouse IgG were used as secondary antibodies. FPV-infected cells were used as the negative control, and b-actin served as the internal control.
To assess the stability of the SIV gag and SIV envT insertions, rFPV Sg-Se was passaged 20 times, and the genomic DNA (gDNA), RNA, and total protein were extracted from the 1st, 5th, 10th, 15th, and 20th passages at the genetic (PCR, RT-PCR) and protein (Western-blot) levels.
Single Immunization
Fifty-four (54) female BABL/c mice were divided evenly into three groups (n = 18). One group was immunized with 1 9 10 6 plaque forming units (PFU) of rFPV Sg-Se (rFPV Sg-Se ) by the intramuscular route, one group received 1 9 10 6 PFU of FPV282E4 (FPV282E4), and one received 100 lL of PBS (PBS). Blood samples were harvested at 1, 7, 14, 21, 28, and 35 days post immunization. The serum was collected and stored at -80°C until it was used in ELISAs to detect the levels of SIV-and vector-specific antibodies. The experimental design is shown in Fig. 2a .
Prime-Boost Immunization
Seventy-two (72) female BALB/c mice were divided into three experimental groups (n = 24). Animals in the rFPV Sg-Se group were primed with 1 9 10 7 PFU of rFPV Sg-Se in 100 lL of PBS by the intramuscular route at day 0 and were boosted with the same dosage at day 21. The second group received 1 9 10 6 PFU of FPV282E4 (FPV282E4) at days 0 and 21, and the third group received 100 lL of PBS on days 0 and 21. Serum sample were collected at days 1, 7, 14, 21, 28, 35, 42, and 49 post immunization to detect SIV and vector-specific antibodies by ELISA. The experimental design is shown in Fig. 3a .
ELISA Analysis and Residual Virus Detection
SIV-specific antibody responses to heterologous SIVmac239 gag and gp120 (env) were detected by ELISA. For the ELISA, the SIV gag and gp120 proteins were utilized as capture antibodies, serum samples from immunized mice were the primary antibody (diluted in 1:20 in PBS) added to the wells, and a peroxidase-conjugated goat antimouse IgG antibody was used as the second antibody (diluted 3000-fold in PBS), and the optical density (OD) was detected at 492 nm. A standard curve was constructed using the same approach. Vector-specific antibodies against inactivated FPV282E4 (1 9 10 6 PFU/ 96 well plate) were detected in the same manner.
gDNA was isolated from the hearts, livers, spleens, lungs, kidneys, brains, and muscles of mice primed with rFPV Sg-Se on days 1, 3, 5, 7, and 14 post immunization for use as templates for amplifying the SIV gag, SIV envT, and P4b genes to detect residual rFPV Sg-Se . The primers utilized are shown in Table 1 .
Statistical Analysis
Statistical analyses were performed using the Graphpad Prism software version 5.0 (San Diego, CA, USA). Differences between groups with a p value \ 0.05 were considered to be statistically significant. Data are presented as the mean ± standard deviation (SD).
Results

Construction and Characterization of the rFPV sg-se Vaccine
To construct rFPV sg-se , we first generated the recombinant plasmid pT3eGFP150-Sg-Se (8509 bp) shown in Fig. 1a . f Western bolt analysis of SIV gag and SIV envT in rFPV Sg-Seinfected BHK cells compared to mock infection. g The SIV gag and SIV envT genes were amplified from the gDNA and cDNA of rFPV Sg-Se -infected CEF cells every five passage (1, 5, 10, 15 and 20) for twenty passages. h Protein expression levels of SIV gag and SIV envT were assessed by Western-blotting every five passages for twenty passages
The successful construction of pT3eGFP150-Sg-Se was confirmed by restriction enzyme digestion using Afl II/ Not I to identify the SIV gag insert (1533 bp) and Kpn I/Sal I to identify the SIV envT insert (2160 bp) as shown in Fig. 1b . Having established the SIV genes were correctly inserted, we then infected CEF cells with FPV282E4 and transfected the infected cells with pT3eGFP150-Sg-Se. The rFPV Sg-Se -infected cells were then selected based on expression of the EGFP reporter gene. Rounds of selection for rFPV Sg-Se continued until all of the plaques expressed EGFP (Fig. 1c) . The SIV gag (1503 bp), SIV envT (2106 bp), P4b (578 bp), and TK (1006 bp) genes were amplified from rFPV-sg-se infected cells by PCR and RT-PCR (Fig. 1d) , indicating that the foreign genes were integrated into the rFPV Sg-Se genome and transcribed. A pure stock of rFPV Sg-Se , lacking contamination from FPV282E4, was obtained when the TK gene could not be amplified from gDNA or cDNA. The target proteins SIV gag (56 kDa) and SIV envT (120 kDa) could be identified in rFPV Sg-Se -infected CEF and BHK cells by Western-blot (Fig. 1e, f) .
To assess the stability of SIV gene expression, gDNA, RNA, and total protein was collected from rFPV Sg-Se infected cells every five passages for 20 passages to assess the integration, transcriptional, and translational levels of SIV gag and SIV envT by PCR, RT-PCR (Fig. 1g) and Western-blot (Fig. 1h) . The results demonstrated that rFPV Sg-Se could be passaged at least 20 times and continue to stably express the inserted SIV genes.
Evaluating the Titer of SIV and FPV Specific Antibodies Elicited by Immunization with rFPV Sg-Se
The ability of rFPV Sg-Se to elicit antibodies targeting SIV gag and gp120 was first assessed following a single Fig. 2 Quantifying the serum antigen specific IgG titer in BALB/c mice following a single rFPV sg-se immunization. a Schematic of the experimental design. Female BALB/c mice were used (n = 18/group). The mice were divided into three groups and immunized with rFPV sg-se , FPV282E4, or PBS. b SIV gag-specific IgG titer, c SIV gp120-specific IgG titer, and d vector-specific antibody levels were measured in the serum by ELISA Fig. 3 Quantifying the serum antigen specific IgG titer in BALB/c mice following a prime-boost rFPV sg-se immunization. a Schematic of the experimental design. Female BALB/c mice were used (n = 24/group). The mice were divided into three groups and immunized with rFPV sg-se , FPV282E4, or PBS. b SIV gag-specific IgG titers, c SIV gp120-specific IgG titers, and d vector-specific antibody levels were measured in the serum by ELISA Fig. 4 Detection of residual virus in organs of rFPV Sg-Se -immunized mice. Residual rFPV Sg-Se was detected by PCR in the heart, liver, spleen, lung, kidney, brain, and muscle of immunized mice at a 1, b 3, c 5, d 7 and e 14 days post immunization immunization (Fig. 2a) . The levels of SIV-and FPV specific IgG antibodies in the serum of immunized mice were measured by ELISA at 1, 7, 14, 21, 28, and 35 days post immunization. Following a single immunization, the levels of SIV gag-and gp120-specific antibodies in the rFPV Sg-Se immunized group were significantly higher than the other groups (p \ 0.05, Fig. 2b, c) . Vector-specific antibody levels were also markedly increased at day 7 post immunization in the rFPV Sg-Se and FPV groups, but plateaued from 14 to 35 days post immunization (Fig. 2d) .
To test whether the antibody response could be boosted, we immunized mice twice on days 0 and 21. The serum antigen specific IgG titers were measured by ELISA on days 1, 7, 14, 21, 28, 35, 42 , and 49 following the priming immunization (Fig. 3A) . The levels of IgG antibodies specific to the SIV gag and gp120 proteins were further increased after boosting (p \ 0.01, Fig. 3b, c) . In contrast, the titer of vector-specific antibodies remained relatively stable after boosting (Fig. 3d) . These results indicated that immunizing BALB/c mice with SIV gag and SIV gp120 in the FPV vector elicited an SIV-specific humoral response, and that a prime-boost strategy elicited higher titers of antibody than a single immunization.
Detection of Residual rFPV Sg-Se in Multiple Organs
As a safety measure and to demonstrate the transient nature of rFPV Sg-Se infection, residual rFPV Sg-Se was detected by amplifying the SIV gag, SIV envT, and p4b genes from the tissues and organs of rFPV Sg-Se -immunized mice at days 1, 3, 5, 7 and 14 post immunization. rFPV Sg-Se detection are shown in Fig. 4a , e, respectively. rFPV Sg-Se was only detected in the muscle at 1, 3, 5, and 7 days post immunization. The preliminary results suggest that gene expression from 1 9 10 6 PFU of rFPV Sg-Se was cleared from the injection site by at most 14 days post immunization in BABL/c mice.
Discussion
To successfully elicit a durable, long-lasting humoral response to protect against HIV-1 and SIV infection over many years multiple immunizations are necessary, which may lead to immune tolerance if the same vaccine is used every time. Therefore, multiple vaccine platforms are necessary to use in combined immunization strategies to prevent HIV and SIV infection over many years.
To make the rFPV Sg-Se vaccine candidate tested in this study, we selected the gag and env genes which are well known to elicit a strong humoral and neutralizing antibody response in humans [22] . In early studies from our laboratory, BrdU selection has been used to construct recombinant vaccinia virus and rFPV vectors, this method generally has a low recombination efficiency, is labor intensive, and returns a high number of non-recombinant viruses during screening. Thus, we chose to use the EGFP reporter gene to construct the rFPV plasmid pT3eGFP150-Sg-Se. This method had the advantages that EGFP was only expressed in the recombinant viruses, and the screening process was visual based on easily observable green fluorescent plaques.
Immunization with rFPV Sg-Se elicited an antigen specific IgG response to SIVmac239 gag and gp120 proteins using a prime-boost strategy. We also observed an antibody response to the FPV vector, which did not increase following the booster immunization. These results indicated that vaccination using rFPV sg-se could be repeated at least once to increase antibody titer.
While we have shown that high levels of SIV-specific antibodies can be elicited by rFPV Sg-Se , future studies are required to characterize the neutralizing antibody titer, cellular immune response, and protective efficacy of the vaccine. In addition, rFPV Sg-Se was not detected in the other organs by PCR, it is possible that rFPV does not bind to organs away from the injection site or that the low number of adsorbed-rFPV Sg-Se virions is not sufficient to detect by PCR. Therefore, we also need to further verify that rFPVsg-se is not widely disseminated and is transiently infecting the recipient. Our work did show that SIV gag-and SIV envT-specific antibodies were elicited strongly by rFPV Sg-Se in the BALB/c mouse model and provided a foundation for testing the immunogenicity and safety research of SIV/HIV rFPV candidate vaccines.
